Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Study Number

4205625

Phase

III

Age Group

Adult

Principal Investigator

Saby George

Purpose

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

Check your eligibility for this trial

Check now

Full Title

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of
Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients
With Advanced Clear Cell Renal Cell Carcinoma

ClinicalTrials.Gov ID

NCT07011719

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.